Sinol USA to license MucoAd for the development of new formulations of Sinol Nasal Sprays

Sept. 19, 2008 - PRLog -- Washington, DC, and Newtown, CT --- Strategic BioSciences and Sinol USA announced today the signing of a Memorandum of Understanding (MOU) signifying their intent to enter into a definitive agreement to develop and market a new formulation of SINOL Nasal Sprays with MucoAd™.  Under the terms of the MOU, Strategic BioSciences will license MucoAd™ to Sinol USA for use in the combined products on a worldwide basis.

MucoAd™ is a non-toxic, non-irritating, liquid mucoadhesive carrier which prolongs the contact time between drug and mucosa.  This patented pharmaceutical composition can be loaded with nearly any pharmaceutical preparation and delivered to nasal, ophthalmic, buccal, vaginal and rectal tissues.  Clinical studies have shown that increasing the contact time of a drug to the mucosa may reduce dosing and/or lower the frequency of administration, thereby achieving the desired therapeutic result with a lower incidence of adverse reactions.  

Sinol USA, headquartered in Newtown, Connecticut, is a healthcare company dedicated to developing products that combine 100% natural ingredients with new innovative technologies.  SINOL Nasal Sprays are available without a prescription for fast relief from allergy and sinus congestion and headaches of all degrees and types.  Following the completion of a clinical study of Sinol+MucoAd™, which is scheduled to commence this month, the new formulation is expected to be available without a prescription during the first quarter of 2009.

Strategic Pharmaceuticals Company, LLC., doing business as Strategic BioSciences, is the joint venture of SRxA Holdings Inc, an affiliate of Strategic Pharmaceutical Advisors of Washington, DC and Fortune Apex Development of Tortola, BVI.  Strategic BioSciences holds the exclusive global rights to MucoAd™. Patents for MucoAd™ have been granted in the United Kingdom and Singapore; and patents are pending in the United States and numerous countries and jurisdictions worldwide.  Strategic BioSciences is headquartered in Washington, DC with offices in London and Hong Kong.

Announcing the planned collaboration and clinical trial, Paul Carpenter, CEO of Sinol USA, Inc. said, “SINOL Nasal Sprays provide consumers with a healthy natural medical alternative for headaches and for nasal congestion associated with sinus and allergy. We look forward to collaborating on the SINOL reformulation, which should offer significant advantages to SINOL users.”

Dr. Christos Efessiou, Strategic BioSciences’ Chief Executive Officer, commented “MucoAd™ represents a unique method of drug delivery, which provides clinical and economic advantages to healthcare professionals and consumers, and offers intellectual property protection to the product licensees.  My colleagues and I are excited at the possibilities that Sinol+MucoAd™ will offer to healthcare professionals and to allergy and headache sufferers.”

Sinol USA and Strategic Pharmaceutical Advisors, the parent company of Strategic BioSciences, also recently announced the signing of a Memorandum of Understanding to enter into a Marketing Agreement for the SINOL+MucoAd™ product line.  For more information visit: www.RxBioSci.com and www.sinolusa.com

# # #

Strategic Pharmaceuticals Company, LLC., doing business as Strategic BioSciences, is the joint venture of SRxA Holdings Inc, an affiliate of Strategic Pharmaceutical Advisors of Washington, DC and Fortune Apex Development of Tortola, BVI. Strategic BioSciences holds the exclusive global rights to MucoAd™. The company is headquartered in Washington, DC with offices in London and Hong Kong.